top of page
Latest News
Search
A New Single-Tablet Option for HIV's "Forgotten Population" Could Change Lives. Will Policy Let It?
New Phase 3 data show a single-tablet regimen of bictegravir/lenacapavir could finally bring one-pill simplicity to long-term HIV survivors locked into complex regimens by decades of drug resistance. The science is closing the treatment gap. Will our policy systems do the same?
Travis Roppolo
Mar 309 min read
Novel Developments: Merck & Gilead Partner on New ARVs
Merck-Gilead partnership on long-acting injectables Islatravir and Lenacapavir for HIV treatment.
Jen Laws
Mar 28, 20213 min read
Painting Roses in the Desert: Despite Medicaid Expansion, Gaps Remain in Arizona
Arizona's restrictive Medicaid formulary limits single-tablet HIV regimens and HCV agents post-expansion.
Jen Laws
Mar 7, 20213 min read
We Need Your Support Today!
bottom of page